Their weight loss was fat loss, not lean muscle loss
Diabetes Spectrum: A Publication of the American Diabetes Association , 30 (3), 202210
As demand for GLP-1 therapies continues to growparticularly for obesity, which affects more than 40 percent of American adultsensuring broad and appropriate access will be key
Adults with fine lines, skin laxity, or UV damage People recovering from tendon/ligament injuries or elective surgery Individuals experiencing shedding or thinning hair Patients with chronic inflammatory skin or gut issues (Contra-indications: pregnancy, active malignancy, Wilsons disease, or known copper allergy) 6
GRP78, glucose-regulated protein 78